Barbara Binzak Blumenfeld was a panelist at the Food and Drug Law Institute (FDLI) Annual Conference. Her panel focused on the state of FDA’s Center for Biologics Evaluation and Research (CBER) programs, initiatives, and enforcement actions. Other panelists included the Director of CBER, Dr. Peter Marks, as well as the Chief Medical Officer and Executive VP of Science and Regulatory Advocacy for PhRMA and the VP of Policy and Regulatory Affairs for the National Organization for Rare Disorders (NORD). Barbara focused her comments on CBER’s regulatory and enforcement efforts involving stem cell therapies.
FDLI was founded in 1949 and is a nonprofit membership organization offering a forum for the food and drug law community to discuss public policy, law, and regulation. Barbara currently serves as the Chair of the Editorial Advisory Board for the Food and Drug Law Journal.